CN102002069A - 一种合成培南类侧链的双环中间体的制备方法及其应用 - Google Patents
一种合成培南类侧链的双环中间体的制备方法及其应用 Download PDFInfo
- Publication number
- CN102002069A CN102002069A CN2010105411859A CN201010541185A CN102002069A CN 102002069 A CN102002069 A CN 102002069A CN 2010105411859 A CN2010105411859 A CN 2010105411859A CN 201010541185 A CN201010541185 A CN 201010541185A CN 102002069 A CN102002069 A CN 102002069A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- reaction
- preparation
- chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical group C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 title abstract description 3
- 230000002194 synthesizing effect Effects 0.000 title abstract description 3
- 125000002619 bicyclic group Chemical group 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 39
- 238000006243 chemical reaction Methods 0.000 claims abstract description 33
- -1 dicyclic compound Chemical class 0.000 claims abstract description 25
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 10
- 239000012190 activator Substances 0.000 claims abstract description 8
- 150000007530 organic bases Chemical class 0.000 claims abstract description 8
- 150000001412 amines Chemical class 0.000 claims abstract description 7
- 238000009833 condensation Methods 0.000 claims abstract description 6
- 230000005494 condensation Effects 0.000 claims abstract description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- 239000000543 intermediate Substances 0.000 claims description 9
- IVRIRQXJSNCSPQ-UHFFFAOYSA-N propan-2-yl carbonochloridate Chemical compound CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 claims description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 8
- 230000035484 reaction time Effects 0.000 claims description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 8
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical group [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 238000007363 ring formation reaction Methods 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 4
- 150000001348 alkyl chlorides Chemical class 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 150000002170 ethers Chemical class 0.000 claims description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 4
- 150000003141 primary amines Chemical class 0.000 claims description 4
- 150000003335 secondary amines Chemical class 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 claims description 4
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical group ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 235000010265 sodium sulphite Nutrition 0.000 claims description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims description 2
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 claims description 2
- 210000005252 bulbus oculi Anatomy 0.000 claims description 2
- 150000001805 chlorine compounds Chemical class 0.000 claims description 2
- PQLFROTZSIMBKR-UHFFFAOYSA-N ethenyl carbonochloridate Chemical group ClC(=O)OC=C PQLFROTZSIMBKR-UHFFFAOYSA-N 0.000 claims description 2
- 150000002460 imidazoles Chemical class 0.000 claims description 2
- DPLVEEXVKBWGHE-UHFFFAOYSA-N potassium sulfide Chemical compound [S-2].[K+].[K+] DPLVEEXVKBWGHE-UHFFFAOYSA-N 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 claims description 2
- UJJDEOLXODWCGK-UHFFFAOYSA-N tert-butyl carbonochloridate Chemical compound CC(C)(C)OC(Cl)=O UJJDEOLXODWCGK-UHFFFAOYSA-N 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 238000009776 industrial production Methods 0.000 abstract 1
- 229910052979 sodium sulfide Inorganic materials 0.000 abstract 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 150000003014 phosphoric acid esters Chemical class 0.000 description 5
- 239000013078 crystal Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 2
- 229960002260 meropenem Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BENKAPCDIOILGV-RQJHMYQMSA-N (2s,4r)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1C[C@H](O)C[C@H]1C(O)=O BENKAPCDIOILGV-RQJHMYQMSA-N 0.000 description 1
- JMJMJDNHVXYAOC-MNOVXSKESA-N (2s,4r)-4-hydroxy-1-[(4-nitrophenyl)methoxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1[C@H](O)C[C@@H](C(O)=O)N1C(=O)OCC1=CC=C([N+]([O-])=O)C=C1 JMJMJDNHVXYAOC-MNOVXSKESA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- HMORXJGLDYBOEV-UHFFFAOYSA-N NC(C1)(C11NCCC1)O Chemical compound NC(C1)(C11NCCC1)O HMORXJGLDYBOEV-UHFFFAOYSA-N 0.000 description 1
- 0 [N+]=*C(CC[C@](C1)N2)=C[C@@]1C2=O Chemical compound [N+]=*C(CC[C@](C1)N2)=C[C@@]1C2=O 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000012658 bimolecular nucleophilic substitution Methods 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960002770 ertapenem Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明涉及一种如下式(I)所示的合成培南侧链的双环中间体的制备方法及其应用。反应路线如下所示。
Description
技术领域
本发明涉及一种合成培南类侧链的关键中间体的制备方法和应用。
背景技术
美罗培南(Meropenem)、尔他培南(Ertapenem)等碳青霉烯类抗生素,从结构上看,都是由培南母核与2,4位取代的吡咯烷侧链(Ⅱ)经化学缩合而成。因此,找到一种合成上述吡咯烷侧链化合物(Ⅱ)的通用的方法,对于合成培南类抗生素方面具有重要意义。
吡咯烷侧链化合物(Ⅱ)的合成,研究比较多的是以L-羟脯氨酸为起始原料,经过N-保护、羧基活化、羟基活化,4-位发生双分子亲核取代反应(SN2反应)翻转构型、活化的羧基与胺缩合、水解反应等步骤得到(Ⅱ)。反应路线如下:
这种制备方法往往合成路线过长,制备过程复杂,总收率不高,而且不是一种通用的简便的制备方法。
为了克服传统方法的缺点,近年来也有一些文献介绍通过先合成双环中间体化合物(如下式(I))来制备培南侧链化合物。但是,这些文献方法都不约而同地存在一些缺陷,如专利US5322952A1,采用了通硫化氢的方法环合,这对环境不友好,不适宜工业化生产;专利US5648501A,对羧基的活化选用二苯基磷酰酯,虽然收率较高,但是价格昂贵成本太高,也不适宜大规模生产。
发明内容
本发明的目的在于,提供一种廉价的、适宜工业化生产的合成培南侧链双环中间体(I)的新方法,以及用该中间体合成相应培南侧链化合物的方法。
以反式-L-羟脯氨酸为起始原料,经N上保护后,用“一锅法”进行羧基活化、羟基活化、再环合得到式(I)化合物;式(I)化合物与对应的胺缩合得到保护的培南侧链化合物,反应路线如下所示。
一种合成培南侧链的双环中间体的制备方法,其特征在于,所述双环中间体
的结构式如下反应路线中的式(I)所示:
所述制备方法如下:
1)式(Ⅲ)化合物在有机碱作用下,与羧基活化剂反应生成式(Ⅳ)化合物,反应温度为-30~-5℃,反应时间为0.5~2h,羧基活化剂与式(Ⅲ)化合物的物质的量比为2.0~1.2:1;
其中,R3为吡咯烷N上的保护基,选自叔丁氧羰基(t-BOC)、对硝基苄氧羰基(PNZ)、苄氧羰基、对甲氧基苄氧羰基、烯丙氧羰基(AOC)、苄氧羰基(Cbz)、二异丙基磷酰基(DIPP)等;
2)式(Ⅳ)化合物在有机碱作用下,与羟基活化剂反应生成式(Ⅴ)化合物,反应温度为-20~-5℃,反应时间为0.5~2h,羟基活化剂与式(Ⅳ)化合物的物质的量比1.5~1.05:1;
3)式(Ⅴ)化合物与硫化物在低温下环合得到双环化合物(Ⅰ),反应温度为-20~0℃,反应时间为1~5h,硫化物与式(Ⅴ)化合物的摩尔比为2~8:1。
所述羧基活化剂是磺酰氯化合物、磺酸酐、烷基氯甲酸酯、烷基酰氯化合物、N,N-羰基二咪唑(CDI)、二环已基碳二亚胺(DCC)、氯甲酸异丙酯或特戊酰氯,优选氯甲酸异丙酯和特戊酰氯。
所述磺酰氯化合物是甲烷磺酰氯、对甲苯磺酰氯或苯磺酰氯;所述磺酸酐是甲磺酸酐或对甲苯磺酸酐;所述烷基氯甲酸酯是氯甲酸乙酯、氯甲酸异丙酯或氯甲酸叔丁酯;所述酰氯化合物是草酰氯或特戊酰氯。
所述有机碱是三乙胺、二异丙基乙胺、吡啶、甲基吡啶、咪唑或喹啉。
所述硫化物是硫化钠、硫氢化钠和硫化钾。
在各反应步骤中用到的溶剂选自醚类、卤代烷烃、乙睛、甲苯、乙酸乙酯或DMF。
所述醚类是环氧乙烷、***或四氢呋喃;所述卤代烷烃是二氯甲烷、氯仿或1,2-二氯乙烷。
所述式(Ⅰ)化合物的应用,其特征在于,所述式(Ⅰ)化合物与胺开环缩合得到培南侧链化合物(Ⅱ),反应式如下:
所述胺是任意一级胺或二级胺,所述一级胺如NH2PhCO2H、NHBSO2NH2等;所述二级胺是HN(CH3)2、HN(CH3)C2H5等。
反应中的溶剂是环氧乙烷、四氢呋喃、乙酸乙酯、甲苯、丙酮、乙酸或DMF;反应温度为0~40℃,反应时间为30min~24h。
本发明的优点:1、双环中间体(Ⅰ) 化合物由“一锅法”制得,合成路线简短,操作简单方便;2、该法通用性好,对于吡咯烷N上保护基为BOC、PNZ、AOC、Cbz 、DIPP、苄氧羰基、对甲氧基苄氧羰基等均适用;3、采用羧基用氯甲酸异丙酯、特戊酰氯等活化,然后用硫化钠环合的方法,原料廉价易得、收率高,能极大地成本降低; 4、该法反应条件温和、环境友好,是一条适宜工业化生产的路线。
具体实施方式
下面,通过以下实施例对本发明作进一步说明,它将有助于理解本发明,但并不限制本发明的内容。
实施例 1
1)二异丙基(1S,4S)-6-氧代-5-硫-2-氮杂双环[2.2.1]庚-2-基磷酸酯
反应瓶中加入90g(0.305mol)的(2S,4R)-1-(二异丙基磷酸基)-4-羟基吡咯烷-2-甲酸和430ml的二氯甲烷,室温下加入35g(0.347mol)的三乙胺。氮气保护下降温到瓶内温度≤-15℃,滴加40.4g(0.335mol)的特戊酰氯,搅拌反应15分钟。再向其中加入40g(0.396mol)的三乙胺,滴加甲烷磺酰氯41.7g(0.335mol),搅拌反应15分钟。温度降到-10℃以下后,加入Na2S.9H2O溶液,搅拌反应1小时。流加3N HCl 200ml,静置分相,水层用120ml二氯甲烷萃取一次,合并有机相,加入32g(0.317mol)三乙胺,加热回流2小时。温度降到0℃,加入1N HCl 200ml。静置分相,有机相分别用水,5%碳酸钠水溶液和饱和盐水洗。减压浓缩蒸干,流加400ml的石油醚,降温到0℃,搅拌2小时,过滤,晶体用MTBE打浆,过滤,40℃烘干。得到产品82g(0.28mol, 收率91.8%)二异丙基(1S,4S)-6-氧代-5-硫-2-氮杂双环[2.2.1]庚-2-基磷酸酯。
Mp: 89~90℃
1H NMR(400MHz,CDCl3)
1.27(d, 3H), 1.29(d, 3H), 1.30(d, 6H), 2.02(m, 1H), 2,13(m, 1H), 3.40(m, 1H), 3.71(m, 1H) , 4.09(m, 1H), 4.20(m, 1H), 4.57(m, 2H)。
实施例 2
2)二异丙基(1S,4S)-6-氧代-5-硫-2-氮杂双环[2.2.1]庚-2-基磷酸酯
将实施例1中的40.4g(0.335mol)的特戊酰氯替换为40g(0.327mol)的氯甲酸异丙酯,其他加量和方法均相同,得到74.3g(0.253mol, 收率91.8%)二异丙基(1S,4S)-6-氧代-5-硫-2-氮杂双环[2.2.1]庚-2-基磷酸酯。
实施例 3
3) (1S,4S)-烯丙氧羰基-6-氧代-5-硫-2-氮杂双环[2.2.1]庚-2-酯的制备
将实施例1中的90g(0.305mol)的(2S,4R)-1-(二异丙基磷酸基)-4-羟基吡咯烷-2-甲酸替换为65g(0.305mol)的(2S,4R)-1-烯丙氧羰基-4-羟基吡咯烷-2-甲酸,其他加量和方法均相同,得到油状物60.4g(0.283mol,收率93%)(1S,4S)-烯丙氧羰基-6-氧代-5-硫-2-氮杂双环[2.2.1]庚-2-酯。
1H NMR(400MHz,CDCl3)
2.18(m, 2H), 3.65(m, 1H), 3.85(d, 1H), 4.14(m, 1H), 4.63(d, 2H), 4.67(m, 1H), 5.22(d, 1H), 5.32(d, 1H), 5.92(m, 1H)。
实施例 4
4) (1S,4S)-烯丙氧羰基-6-氧代-5-硫-2-氮杂双环[2.2.1]庚-2-酯的制备
将实施例3中的特戊酰氯替换为40g(0.327mol)的氯甲酸异丙酯,其他加量和方法均相同,得到标题化合物油状物60.7g(0.284mol,收率93.4%)(1S,4S)-烯丙氧羰基-6-氧代-5-硫-2-氮杂双环[2.2.1]庚-2-酯。
实施例 5
5) (1S,4S)-叔丁氧羰基-6-氧代-5-硫-2-氮杂双环[2.2.1]庚-2-酯的制备
将实施例1中的90g(0.305mol)的(2S,4R)-1-(二异丙基磷酸基)-4-羟基吡咯烷-2-甲酸替换为70.4g(0.305mol)的(2S,4R)-1-(叔丁氧羰基)-4-羟基吡咯烷-2-甲酸,其他加量和方法均相同,得到白色固体63.7g(0.278mol,收率91.2%)(1S,4S)- 叔丁氧羰基-6-氧代-5-硫-2-氮杂双环[2.2.1]庚-2-酯。
Mp: 91℃
1H NMR(400MHz,CD2Cl2)
1.42(s, 9H), 2.07(dt, 1H), 2.13(m, 1H), 3.48-3.53(m, 1H), 3.74(m, 1H), 4.11(m, 1H), 4.42-4.53(d, 1H)。
实施例 6
6) (1S,4S)-叔丁氧羰基-6-氧代-5-硫-2-氮杂双环[2.2.1]庚-2-酯的制备
将实施例5中的特戊酰氯替换为41.3g(0.337mol)的氯甲酸异丙酯,三乙胺用相当量的二异丙基乙胺代替,其他反应方式相同,得到标题化合物白色固体65.6g(0.286mol,收率94%)(1S,4S)- 叔丁氧羰基-6-氧代-5-硫-2-氮杂双环[2.2.1]庚-2-酯。
实施例 7
7) (1S,4S)-4-硝基苄氧羰基-6-氧代-5-硫-2-氮杂双环[2.2.1]庚-2-酯的制备
将实施例1中的90g(0.305mol)的(2S,4R)-1-(二异丙基磷酸基)-4-羟基吡咯烷-2-甲酸替换为94.5g(0.305mol)的(2S,4R)-1-((4-硝基苄氧)羰基)-4-羟基吡咯烷-2-甲酸,三乙胺用相应当量的DIPEA替代,其他加量和方法均相同,得到浅黄色固体79.4g(0.258mol,收率84.5%)(1S,4S)-4-硝基苄氧羰基-6-氧代-5-硫-2-氮杂双环[2.2.1]庚-2-酯。
Mp: 102~103℃
1H NMR(400MHz,CDCl3)
2.11-2.27(m, 2H), 3.67-3.72(m, 1H), 3.85-3.90(m, 1H), 4.15-4.19(m, 1H), 4.62-4.70(m, 1H), 5.21(d, 1H), 5.31(d, 1H), 7.54(d, 2H),8.23(d, 2H)。
实施例 8
8) (1S,4S)-4-硝基苄氧羰基-6-氧代-5-硫-2-氮杂双环[2.2.1]庚-2-酯的制备
将实施例7中的特戊酰氯用为40g(0.327mol)氯甲酸异丙酯替代,其他加量和反应方法相同,得到标题化合物浅黄色固体82.6g(0.268mol,收率88%)(1S,4S)-4-硝基苄氧羰基-6-氧代-5-硫-2-氮杂双环[2.2.1]庚-2-酯。
实施例 9
9)3-((3S,5S)-1-(二异丙基磷酰基)-3-巯基吡咯烷-5-甲酰胺基)苯甲酸的制备
将45.3g(0.148mol) 二异丙基(1S,4S)-6-氧代-5-硫-2-氮杂双环[2.2.1]庚-2-基磷酸酯和22.7g(0.164mol)间氨基苯甲酸溶于250ml冰醋酸中,室温下反应16h,向其中加入600ml 二氯甲烷和300ml 1M盐酸,抽提有机层,浓缩,用乙酸乙酯和环己烷重结晶,得白色晶体59.2g(0.138mol, 收率93%)3-((3S,5S)-1-(二异丙基磷酰基)-3-巯基吡咯烷-5-甲酰胺基)苯甲酸。
Mp: 95~96℃
1H NMR(400MHz,CDCl3)
1.16(s, 12H), 1.50(s, 1H), 2.07-2.32(m, 2H), 2.65-2.76(m, 1H), 2.90-2.94(m, 1H), 3.06-3.10(m, 1H), 3.57-3.65(m, 2H), 3.71-3.74(m, 1H), 7.45-7.48(m, 1H), 7.87-8.0(m, 3H), 8.50-8.53(m, 1H), 10.9(S, 1H)。
实施例 10
10)(2S,4S)-4-硝基苄基 2-(二甲基氨基甲酰基)-4-巯基吡咯烷-1-甲酸酯的制备
反应瓶中加入300ml丙酮和50g(0.162mol) (1S,4S)-4-硝基苄氧羰基-6-氧代-5-硫-2-氮杂双环[2.2.1]庚-2-酯,溶清。降温至10℃,加入19.8g(0.244mol)的二甲胺盐酸盐。控制温度在15~20℃,滴加24.6g三乙胺,在相同温度下反应30分钟后, 减压浓缩丙酮。向其中加入410ml乙酸乙酯和1N HCl,静置分相。向有机相中加入2.79g三丁基膦、180ml的10%盐水,180ml的饱和盐水,浓缩有机相,有大量晶体析出。离心过滤,真空烘干,得白色晶体52.2g(0.148mol,收率87%) (2S,4S)-4-硝基苄基 2-(二甲基氨基甲酰基)-4-巯基吡咯烷-1-甲酸酯。
Mp: 117-119℃
1H NMR(400MHz,CDCl3)
1.56(d, 1H), 1.96-2.21(m, 2H), 2.65-2.71(m, 1H), 2.97(s, 3H), 3.08(s, 3H), 3.48-3.73(m, 2H),4.29-4.31(m, 1H), 5.19(s, 2H), 7.48(d, 2H), 8.15(d, 2H)。
Claims (9)
1.一种合成培南侧链的双环中间体的制备方法,其特征在于,所述双环中间体
的结构式如下反应路线中的式(I)所示:
所述制备方法如下:
1)式(Ⅲ)化合物在有机碱作用下,与羧基活化剂反应生成式(Ⅳ)化合物,反应温度为-30~-5℃,反应时间为0.5~2h,羧基活化剂与式(Ⅲ)化合物的物质的量比为2.0~1.2:1;
其中,R3为吡咯烷N上的保护基,选自叔丁氧羰基、对硝基苄氧羰基、苄氧羰基、对甲氧基苄氧羰基、烯丙氧羰基、苄氧羰基或二异丙基磷酰基;
2)式(Ⅳ)化合物在有机碱作用下,与羟基活化剂反应生成式(Ⅴ)化合物,反应温度为-20~-5℃,反应时间为0.5~2h,羟基活化剂与式(Ⅳ)化合物的物质的量比1.5~1.05:1;
3)式(Ⅴ)化合物与硫化物在低温下环合得到双环化合物(Ⅰ),反应温度为-20~0℃,反应时间为1~5h,硫化物与式(Ⅴ)化合物的摩尔比为2~8:1。
2.根据权利要求1所述的制备方法,其特征在于,所述羧基活化剂是磺酰氯化合物、磺酸酐、烷基氯甲酸酯、烷基酰氯化合物、N,N-羰基二咪唑或二环已基碳二亚胺、特戊酰氯或氯甲酸异丙酯。
3.根据权利要求2所述的制备方法,其特征在于,所述磺酰氯化合物是甲烷磺酰氯、对甲苯磺酰氯或苯磺酰氯;所述磺酸酐是甲磺酸酐或对甲苯磺酸酐;所述烷基氯甲酸酯是氯甲酸乙酯、氯甲酸异丙酯或氯甲酸叔丁酯;所述酰氯化合物是草酰氯或特戊酰氯。
4.根据权利要求1所述的制备方法,其特征在于,所述有机碱是三乙胺、二异丙基乙胺、吡啶、甲基吡啶、咪唑或喹啉。
5.根据权利要求1所述的制备方法,其特征在于,所述硫化物是硫化钠、硫氢化钠或硫化钾。
6.根据权利要求1所述的制备方法,其特征在于,在各反应步骤中用到的溶剂选自醚类、卤代烷烃、乙睛、甲苯、乙酸乙酯或DMF。
7.根据权利要求6所述的制备方法,其特征在于,所述醚类是环氧乙烷、***或四氢呋喃;所述卤代烷烃是二氯甲烷、氯仿或1,2-二氯乙烷。
9.根据权利要求8所述式(Ⅰ)化合物的应用,其特征在于,所述一级胺是NH2PhCO2H或NHBSO2NH2;所述二级胺是HN(CH3)2或HN(CH3)C2H5。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010105411859A CN102002069A (zh) | 2010-11-12 | 2010-11-12 | 一种合成培南类侧链的双环中间体的制备方法及其应用 |
PCT/CN2011/001588 WO2012062036A1 (zh) | 2010-11-12 | 2011-09-19 | 一种含培南类侧链的双环中间体的制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010105411859A CN102002069A (zh) | 2010-11-12 | 2010-11-12 | 一种合成培南类侧链的双环中间体的制备方法及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102002069A true CN102002069A (zh) | 2011-04-06 |
Family
ID=43809795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010105411859A Pending CN102002069A (zh) | 2010-11-12 | 2010-11-12 | 一种合成培南类侧链的双环中间体的制备方法及其应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN102002069A (zh) |
WO (1) | WO2012062036A1 (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012062036A1 (zh) * | 2010-11-12 | 2012-05-18 | 上海巴迪生物医药科技有限公司 | 一种含培南类侧链的双环中间体的制备方法及其应用 |
CN102976994A (zh) * | 2012-12-27 | 2013-03-20 | 天津市敬业精细化工有限公司 | 晶体形态美罗培南侧链及其制备方法 |
CN110386942A (zh) * | 2019-07-12 | 2019-10-29 | 天津大学 | 一种美罗培南侧链中间体硫醇内酯的制备方法 |
CN111484506A (zh) * | 2020-04-16 | 2020-08-04 | 天津大学 | 添加表面活性剂改进美罗培南侧链中间体硫醇内酯的制备方法 |
CN114437043A (zh) * | 2022-02-02 | 2022-05-06 | 浙江乐普药业股份有限公司 | 一种抗新冠药物Nirmatrelvir的制备方法 |
CN114773248A (zh) * | 2022-05-11 | 2022-07-22 | 湖北华洲药业有限公司 | 一种美罗培南侧链的连续化生产方法及装置 |
CN115490625A (zh) * | 2022-11-18 | 2022-12-20 | 山东鑫泉医药有限公司 | 美罗培南侧链的合成及精制方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5322952A (en) * | 1992-01-10 | 1994-06-21 | Sumitomo Pharmaceuticals Company, Limited | Pyrrolidine derivatives and process for preparing the same |
US5721368A (en) * | 1996-07-22 | 1998-02-24 | Merck & Co. Inc. | Process for synthesizing carbapenem side chain intermediates |
CN1486316A (zh) * | 2000-11-20 | 2004-03-31 | ������������ʽ���� | 卡巴培南类抗菌剂的制造方法 |
WO2010073706A1 (ja) * | 2008-12-25 | 2010-07-01 | 株式会社カネカ | カルバペネム側鎖中間体の改良された製造方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101481346B (zh) * | 2009-02-23 | 2011-06-15 | 浙江海翔药业股份有限公司 | 一种碳青霉烯类抗生素侧链的制备方法 |
CN102002069A (zh) * | 2010-11-12 | 2011-04-06 | 上海巴迪生物医药科技有限公司 | 一种合成培南类侧链的双环中间体的制备方法及其应用 |
CN102134249B (zh) * | 2010-12-30 | 2015-11-25 | 天津市敬业精细化工有限公司 | 一种手性5-保护-2-硫杂-5-氮杂双环[2.2.1]庚-3-酮的制备方法 |
-
2010
- 2010-11-12 CN CN2010105411859A patent/CN102002069A/zh active Pending
-
2011
- 2011-09-19 WO PCT/CN2011/001588 patent/WO2012062036A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5322952A (en) * | 1992-01-10 | 1994-06-21 | Sumitomo Pharmaceuticals Company, Limited | Pyrrolidine derivatives and process for preparing the same |
US5721368A (en) * | 1996-07-22 | 1998-02-24 | Merck & Co. Inc. | Process for synthesizing carbapenem side chain intermediates |
CN1486316A (zh) * | 2000-11-20 | 2004-03-31 | ������������ʽ���� | 卡巴培南类抗菌剂的制造方法 |
WO2010073706A1 (ja) * | 2008-12-25 | 2010-07-01 | 株式会社カネカ | カルバペネム側鎖中間体の改良された製造方法 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012062036A1 (zh) * | 2010-11-12 | 2012-05-18 | 上海巴迪生物医药科技有限公司 | 一种含培南类侧链的双环中间体的制备方法及其应用 |
CN102976994A (zh) * | 2012-12-27 | 2013-03-20 | 天津市敬业精细化工有限公司 | 晶体形态美罗培南侧链及其制备方法 |
CN110386942A (zh) * | 2019-07-12 | 2019-10-29 | 天津大学 | 一种美罗培南侧链中间体硫醇内酯的制备方法 |
CN111484506A (zh) * | 2020-04-16 | 2020-08-04 | 天津大学 | 添加表面活性剂改进美罗培南侧链中间体硫醇内酯的制备方法 |
CN114437043A (zh) * | 2022-02-02 | 2022-05-06 | 浙江乐普药业股份有限公司 | 一种抗新冠药物Nirmatrelvir的制备方法 |
CN114773248A (zh) * | 2022-05-11 | 2022-07-22 | 湖北华洲药业有限公司 | 一种美罗培南侧链的连续化生产方法及装置 |
CN114773248B (zh) * | 2022-05-11 | 2023-11-03 | 湖北华洲药业有限公司 | 一种美罗培南侧链的连续化生产方法及装置 |
CN115490625A (zh) * | 2022-11-18 | 2022-12-20 | 山东鑫泉医药有限公司 | 美罗培南侧链的合成及精制方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2012062036A1 (zh) | 2012-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102002069A (zh) | 一种合成培南类侧链的双环中间体的制备方法及其应用 | |
BR112012006053A2 (pt) | processo para preparação do éster metílico do ácido 3-[(4s)-8-bromo-metil-6-(2-piridinil)-4h-imidazol[1,2-a][1,4]benzodiazepin-4-il]propiônico ou sal de benzeno sulfonato do mesmo, e compostos utilizados em tais processos | |
ES2847239T3 (es) | Procedimientos para la preparación de 4-alcoxi-3-(acil o alquil)oxipicolinamidas | |
CN108997187A (zh) | 一种N(π)-甲基-L-组氨酸衍生物的制备方法及其在合成鲸肌肽中的应用 | |
AU2018344099B2 (en) | A simple process for preparing avibactam | |
CN102264744A (zh) | 碳青霉烯侧链中间体的改良制造方法 | |
WO2016045416A1 (zh) | 一种用于合成帕罗西汀的中间体及其制备方法和用途 | |
TWI383974B (zh) | 用於製備(3s,4s)-4-((r)-2-(苯甲氧基)十三基)-3-己基-2-氧雜環丁酮之方法以及用於該方法之新穎中間產物 | |
CN103848851A (zh) | 一种盐酸头孢卡品酯的合成方法 | |
CN104725292A (zh) | 一种(s)(-)-氨磺必利的制备方法 | |
CN113717197B (zh) | 抗结核药物Pretomanid的制备方法及其应用 | |
KR102295388B1 (ko) | 광학 활성 다이아민 유도체 및 티아졸 유도체의 생산을 위한 새로운 합성경로 | |
CN101921237B (zh) | 一种4-乙基-2,3-双氧代哌嗪-1-甲酸酯的制备方法 | |
PT1607090E (pt) | Azimadolina para o tratamento da síndrome do cólon irritável | |
EP3564219B1 (en) | Process for preparing oxadiazacyclo compound and use thereof | |
CN105237492A (zh) | 一种依折麦布中间体的合成方法 | |
CN101128449A (zh) | 制备多西他赛的方法 | |
CN102827191B (zh) | 一种氧头孢类化合物的制备方法 | |
Nain Singh et al. | Facile and Chemoselective Reduction of Carboxylic Acids into Alcohols via Sodium Borohydride Reduction of N‐Acylbenzotriazoles | |
FI66174B (fi) | Foerfarande foer framstaellning av pyridinkarboxylsyra-piperazider | |
CN104086475A (zh) | 一种n-苄氧羰基-l-脯氨酰胺的制备方法 | |
JP2016510740A (ja) | イソヘキシドモノトリフレートおよびそれを合成するプロセス | |
CN103012261B (zh) | 一种孟鲁司特钠及其中间体的制备方法 | |
CN113549063B (zh) | 一种光学异构的八氢-2H-吡咯并[3,4-c]吡啶-2-羧酸叔丁酯的制备方法 | |
CN114773256B (zh) | 一种4-氰基哌啶的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110406 |